European Union - English - EMA (European Medicines Agency)

serono europe limited - efalizumab - psoriasis - immunosuppressants - treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and puva (see section 5.1 - clinical efficacy).

Israel - English - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

Israel - English - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 88 mcg/ml - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiplbe sclerosis has not been established.rebif is indicated for the treatment of patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - solution for injection - lutropin alfa 150 iu / 0.48 ml; follitropin alfa 300 iu / 0.48 ml - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in adult women with sever lh and fsh deficiency.in clinical trials, these patients were defined by an endogenous serum lh level < 1.2iu/l

Israel - English - Ministry of Health

merck serono ltd - cetuximab - solution for infusion - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, ras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - follitropin alfa - powder and solvent for solution for injection - 450unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - follitropin alfa - powder and solvent for solution for injection - 1050unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - follitropin alfa - powder and solvent for solution for injection - 75unit

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

merck serono europe ltd, united kingdom - interferon beta-1a - solution for injection in cartridge - 18000000 iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

merck serono europe ltd, united kingdom - interferon beta-1a - solution for injection in cartridge - 36000000 iu